Pneumokoniosis

01Pathophysiology

Pneumoconiosis is not a single disease but a family of interstitial lung diseases caused by chronic inhalation of inorganic (mineral) dusts. The unifying mechanism across all subtypes is that inhaled particles, typically 1 to 5 micrometers in diameter, deposit in the terminal bronchioles and alveoli, where they are engulfed by alveolar macrophages. These macrophages cannot fully degrade the mineral particles, triggering a sustained inflammatory cascade with release of cytokines (TNF-alpha, IL-1, fibrogenic growth factors such as TGF-beta and PDGF). Over time, this leads to collagen deposition and progressive pulmonary fibrosis.

The reason these patients present with slowly worsening dyspnea is that fibrosis thickens the alveolar-capillary membrane, impairing gas exchange. This manifests on pulmonary function testing as a restrictive pattern (decreased FVC and TLC) with a reduced diffusing capacity for carbon monoxide (DLCO). As the disease progresses, destruction of the pulmonary vascular bed leads to pulmonary hypertension and eventually cor pulmonale (right-sided heart failure), which is the most common cause of death in advanced pneumoconiosis.

A critical concept for exam purposes is that the type of dust determines the pattern of fibrosis, its distribution in the lung, and the associated complications. Silica and asbestos are fibrogenic dusts, meaning they directly cause progressive fibrosis. Coal dust is relatively inert in small amounts but causes disease through sheer volume of accumulation. Beryllium is unique because it triggers a type IV hypersensitivity (granulomatous) reaction, making berylliosis clinically and histologically indistinguishable from sarcoidosis.

02Classification and Clinical Manifestation

Clinical Forms of Silicosis

03Diagnostic Workup

The best initial test for any patient with chronic dyspnea and occupational dust exposure is a chest X-ray combined with a detailed occupational history. The occupational history is arguably the single most important diagnostic element, because without knowing the exposure, the imaging pattern alone is often nondiagnostic.

On CXR, the key patterns to recognize are:

For silicosis, look for small, rounded opacities predominantly in the upper lung zones with eggshell calcification of hilar lymph nodes. Eggshell calcification refers to thin, rim-like calcification around the periphery of the lymph node, and this finding on an exam is virtually pathognomonic for silicosis (though it can rarely occur in sarcoidosis, treated lymphoma, or post-radiation). When these nodules coalesce into masses greater than 1 cm, this is termed progressive massive fibrosis (PMF), also known as complicated silicosis.

For asbestosis, the parenchymal disease affects the lower lobes with interstitial fibrosis appearing as reticular or reticulonodular opacities. The hallmark radiographic finding is calcified pleural plaques on the parietal pleura, particularly along the diaphragm and lateral chest wall. Pleural plaques indicate asbestos exposure but do not by themselves indicate asbestosis (parenchymal disease). This distinction is frequently tested.

For coal workers' pneumoconiosis, small rounded opacities appear in the upper lobes, and complicated CWP shows large opacities (PMF) similar to silicosis.

HRCT is more sensitive than plain radiography and is used when the CXR is equivocal or for better characterization. It can identify early interstitial changes, ground-glass opacities, and subtle pleural plaques missed on CXR.

PFTs are essential for quantifying functional impairment. The classic pattern is restrictive (reduced FVC and TLC) with decreased DLCO. However, early disease or coal dust exposure may show a mixed obstructive-restrictive pattern, especially if the patient is also a smoker.

For berylliosis, the diagnosis requires the BeLPT (Beryllium Lymphocyte Proliferation Test), which is the key discriminator from sarcoidosis. Both diseases produce non-caseating granulomas, bilateral hilar lymphadenopathy, and elevated ACE levels, but only berylliosis will have a positive BeLPT. This test is considered the most accurate diagnostic tool for berylliosis.

In patients with silicosis, always screen for tuberculosis with PPD or IGRA. Silica impairs macrophage function, creating a 3 to 30-fold increased risk of developing TB. If a silicosis patient acutely worsens, TB should be at the top of the differential.

Lung biopsy is the gold standard but is rarely required when the occupational history and imaging are concordant. When performed, the pathologist looks for ferruginous bodies (asbestosis), which are golden-brown, fusiform, beaded rods consisting of asbestos fibers coated with hemosiderin and glycoprotein. Under polarized light, birefringent particles can be identified in silicosis and talcosis.

04Management and Treatment

There is no curative treatment for any form of pneumoconiosis. The fibrosis that has already occurred is irreversible. This is a fundamental concept for exam questions: the answer is never a drug that "reverses" the fibrosis.

The first and most important step in management, regardless of subtype or severity, is removal from further dust exposure. This is the "next best step" answer whenever the vignette describes an actively exposed worker. This single intervention is the only proven measure to slow disease progression.

Smoking cessation is critically important, particularly in asbestosis. Asbestos exposure alone increases the risk of bronchogenic carcinoma by approximately 5-fold. Cigarette smoking alone increases the risk by approximately 10-fold. The combination is multiplicative (not merely additive), increasing the risk by approximately 50 to 55-fold. This synergistic relationship is one of the most frequently tested facts about asbestosis.

For silicosis with positive tuberculin skin testing, isoniazid prophylaxis (300 mg daily for 9 months) is recommended even without active TB, because silica-laden macrophages are functionally impaired, making latent TB far more likely to reactivate. If active TB develops (silico-tuberculosis), standard multi-drug TB therapy is indicated, though treatment duration may be extended due to poor drug penetration into fibrotic tissue.

Berylliosis is the only pneumoconiosis that responds to corticosteroids, because the underlying mechanism is a granulomatous hypersensitivity reaction rather than simple fibrosis. Prednisone is initiated at 20 to 40 mg/day and tapered over weeks to months based on clinical and radiographic response. Many patients require long-term low-dose maintenance therapy. Steroid-sparing agents (methotrexate, azathioprine) can be considered for patients with intolerable steroid side effects.

For acute silicoproteinosis, the treatment of choice is whole lung lavage, which physically washes out the accumulated proteinaceous material from the alveoli. This is the same procedure used for pulmonary alveolar proteinosis.

All patients should receive influenza and pneumococcal vaccinations to reduce infection risk. Supplemental oxygen is prescribed for patients meeting standard criteria for long-term oxygen therapy. Lung transplantation remains the final option for end-stage disease with progressive respiratory failure despite maximal supportive care.

Regarding cancer surveillance in asbestos-exposed patients: the two malignancies to watch for are bronchogenic carcinoma (the more common cancer, risk amplified by smoking) and malignant mesothelioma (less common but almost exclusively caused by asbestos, unrelated to smoking). The latency period for mesothelioma is typically 25 to 45 years after initial exposure.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way students lose points on pneumoconiosis questions is by confusing the lobe distribution. Silicosis and coal workers' pneumoconiosis affect the upper lobes, while asbestosis affects the lower lobes. When a vignette describes a construction worker with lower-lobe fibrosis and pleural plaques, the answer is asbestosis, not silicosis, even though both are occupational lung diseases.

The second classic trap involves pleural plaques versus asbestosis. Pleural plaques indicate asbestos exposure but do not constitute asbestosis. Asbestosis requires parenchymal (interstitial) fibrosis. A patient with isolated pleural plaques but clear lung parenchyma has asbestos exposure, not asbestosis. This distinction matters for questions about diagnosis and disability.

Another frequently tested trap is the berylliosis versus sarcoidosis distinction. If the vignette describes a patient working in aerospace or electronics manufacturing with bilateral hilar lymphadenopathy and non-caseating granulomas, the answer is berylliosis, not sarcoidosis. The BeLPT confirms it.

Students also miss the multiplicative cancer risk with asbestos and smoking. If asked which intervention most reduces lung cancer risk in an asbestos-exposed smoker, the answer is smoking cessation (not removal from asbestos, though both matter). Mesothelioma, by contrast, is unrelated to smoking and is associated almost exclusively with asbestos (especially the amphibole subtypes like crocidolite).

Finally, any time a patient with known silicosis develops acute clinical worsening with fever, weight loss, or new cavitary lesions, think tuberculosis first. The impaired macrophage function caused by silica particles makes these patients uniquely susceptible, and TB screening is a mandatory part of the workup.

The core competency tested across pneumoconiosis questions is the ability to link a stated occupation to a dust type, then to a radiographic pattern, and finally to the correct diagnosis and its unique complications. The occupational history is the anchor of every vignette. Without it, the imaging findings overlap considerably. With it, the diagnosis becomes straightforward.